On Friday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: Akorn, Inc. (NASDAQ:AKRX), Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP), Harris Corporation (NYSE:HRS), Celldex Therapeutics, Inc. (NASDAQ:CLDX)
Akorn, Inc. (NASDAQ:AKRX), with shares gained 4.78%, closed at $48.48.
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP), with shares jumped 4.74%, settled at $4.31.
Harris Corporation (NYSE:HRS), with shares climbed 4.74%, and closed at $76.75.
Celldex Therapeutics, Inc. (NASDAQ:CLDX), surged 4.66%, and closed at $27.17.
Latest NEWS regarding these Stocks are depicted underneath:
Akorn, Inc. (NASDAQ:AKRX)
Akorn, Inc. (AKRX), filed its Annual Report on Form 10-K for the year ended December 31, 2014 with the U.S. Securities and Exchange Commission SEC on March 17, 2015.
Akorn, Inc. develops, manufactures, and markets generic and branded prescription pharmaceuticals, in addition to animal and over-the-counter OTC consumer health products in the United States and internationally. It operates through two segments, Prescription Pharmaceuticals and Consumer Health.
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)
Formerly on March 16, Synergy Pharmaceuticals, Inc. (SGYP), stated its financial results and business update for the fourth quarter and the year ended December 31, 2014.
Net cash offered by financing activities was $217.1 million during the year ended December 31, 2014, as contrast to $89.2 million offered during the year ended December 31, 2013.
Net cash used in operating activities during the year ended December 31, 2014 was $89.1 million as contrast to $52.6 million of cash used in operating activities during the twelve months ended December 31, 2013.
Net loss for the year ended December 31, 2014 was $95.7 million or $1.02 per share as contrast to $62.1 million or $0.73 per share for the year ended December 31, 2013.
Net loss for the quarter ended December 31, 2014 was $30.6 million, or $0.32 per share, as contrast to $19.9 million or $0.22 per share, for the quarter ended December 31, 2013.
Interest expense on the Notes totaled $2.5 million, or $0.03 per share, during the quarter ended December 31, 2014, whereas the company had no such expense during the quarter ended December 31, 2013.
Synergy Pharmaceuticals Inc., a biopharmaceutical corporation, focuses on the development of drugs to treat gastrointestinal GI disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders; and for the treatment of constipation-predominant irritable bowel syndrome GI disorders.
Harris Corporation (NYSE:HRS)
Formerly on March 19, Harris Corporation (HRS), has been awarded a contract by the Defense Information Systems Agency DISA with a potential value of $450 million to provide systems engineering and program administration services for the agency’s Crisis Administration System CMS. The single-award IDIQ contract has a one-year base and nine one-year options.
The CMS provides government leaders with video and voice communications, powered by a secure, high-performance network. This enables senior U.S. government officials to exchange high-interest, time-sensitive information for critical decision making during emergency situations.
Harris has supported the CMS since 2004 and will continue to provide 24/7 on-call, on-site corrective maintenance for all related hardware and software components. Engineering support will comprise design, development, integration, test, installation, training, and documentation for all enhancements to the CMS.
Harris Corporation, together with its auxiliaries, operates as an international communications and information technology corporation worldwide. The corporation operates through RF Communications, Integrated Network Solutions, and Government Communications Systems segments.
Celldex Therapeutics, Inc. (NASDAQ:CLDX)
Formerly on March 17, Celldex Therapeutics, Inc. (CLDX), declared that it has reached a clinical trial partnership with Roche to evaluate the safety, tolerability and preliminary efficacy of varlilumab, Celldex’s CD27 targeting investigational antibody, and MPDL3280A anti-PDL1, Roche’s investigational cancer immunotherapy in a Phase 1/2 study in renal cell carcinoma.
Varlilumab and MPDL3280A are part of a new class of investigational medicines known as cancer immunotherapies that are designed to harness the body’s own immune system to fight cancer through separate yet complementary mechanisms of action that may enable the activation of T cells, restoring their ability to effectively detect and attack tumor cells. Preclinical data suggest the combination of these two mechanisms are synergistic and may enhance anti-tumor immune response contrast to either agent alone. In Celldex’s Phase 1 study of varlilumab in multiple solid tumors, promising signs of clinical activity in patients with refractory renal cell carcinoma were observed, counting a durable partial response 11.0+ months that has continued to decrease in tumor volume over time and prolonged stable disease 4 patients with a range of 5.3 to 30.7+ months.
Celldex Therapeutics, Inc., a biopharmaceutical corporation, develops, manufactures, and commercializes novel therapeutics for human health care in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
